Table 1.

New thyroid hormone prescriptions in the US, 2010-2020

		TH therapy classes
Year	Adults with new TH prescription	LT4 monotherapy		LT3 therapy (no DTE)		DTE therapy (no LT3)		Other
	n	n	%	n	%	n	%	n	%
2010	56 077	51 495	91.8	1371	2.4	3049	5.4	162	0.3
2011	69 907	63 572	90.9	1352	1.9	4841	6.9	142	0.2
2012	77 484	70 018	90.4	1422	1.8	5861	7.6	183	0.2
2013	61 508	55 471	90.2	1148	1.9	4742	7.7	147	0.2
2014	62 564	55 564	88.8	1119	1.8	5709	9.1	172	0.3
2015	49 520	43 142	87.1	905	1.8	5338	10.8	135	0.3
2016	44 204	38 577	87.3	722	1.6	4783	10.8	122	0.3
2017	34 889	29 866	85.6	719	2.1	4178	12.0	126	0.4
2018	25 574	21 911	85.7	609	2.4	2946	11.5	108	0.4
2019	24 910	21 502	86.3	590	2.4	2728	11.0	90	0.4
2020	18 181	15 860	87.2	409	2.2	1861	10.2	51	0.3
Mean (SD)	47 710.7	42 452.5	88.3	942.4	2.0	4185.1	9.4	130.7	0.3%

Only patients with a diagnosis of primary or subclinical hypothyroidism from the patient claims dataset are included.

Abbreviations: DTE, desiccated thyroid extract; LT3, liothyronine; LT4, levothyroxine; TH, thyroid hormone.